CELYAD ONCOLOGY (CYAD.BR) Fundamental Analysis & Valuation

EBR:CYAD • BE0974260896

0.379 EUR
+0.02 (+5.28%)
Last: Mar 5, 2026, 09:00 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This CYAD.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Overall CYAD gets a fundamental rating of 1 out of 10. We evaluated CYAD against 75 industry peers in the Biotechnology industry. CYAD may be in some trouble as it scores bad on both profitability and health. CYAD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. CYAD.BR Profitability Analysis

1.1 Basic Checks

  • In the past year CYAD has reported negative net income.
  • CYAD had a negative operating cash flow in the past year.
  • CYAD had negative earnings in each of the past 5 years.
  • In the past 5 years CYAD always reported negative operating cash flow.
CYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFCYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • CYAD's Return On Assets of -113.29% is on the low side compared to the rest of the industry. CYAD is outperformed by 76.00% of its industry peers.
Industry RankSector Rank
ROA -113.29%
ROE N/A
ROIC N/A
ROA(3y)-106.06%
ROA(5y)-75.47%
ROE(3y)-740.65%
ROE(5y)-467.64%
ROIC(3y)N/A
ROIC(5y)N/A
CYAD.BR Yearly ROA, ROE, ROICCYAD.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

  • The Gross Margin of CYAD (94.09%) is better than 86.67% of its industry peers.
  • In the last couple of years the Gross Margin of CYAD has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for CYAD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
CYAD.BR Yearly Profit, Operating, Gross MarginsCYAD.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. CYAD.BR Health Analysis

2.1 Basic Checks

  • CYAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CYAD remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for CYAD has been increased compared to 5 years ago.
  • Compared to 1 year ago, CYAD has a worse debt to assets ratio.
CYAD.BR Yearly Shares OutstandingCYAD.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYAD.BR Yearly Total Debt VS Total AssetsCYAD.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -6.19, we must say that CYAD is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -6.19, CYAD is doing worse than 73.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.19
ROIC/WACCN/A
WACC7.54%
CYAD.BR Yearly LT Debt VS Equity VS FCFCYAD.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • CYAD has a Current Ratio of 0.66. This is a bad value and indicates that CYAD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CYAD has a Current ratio of 0.66. This is in the lower half of the industry: CYAD underperforms 78.67% of its industry peers.
  • A Quick Ratio of 0.59 indicates that CYAD may have some problems paying its short term obligations.
  • The Quick ratio of CYAD (0.59) is worse than 76.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.66
Quick Ratio 0.59
CYAD.BR Yearly Current Assets VS Current LiabilitesCYAD.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CYAD.BR Growth Analysis

3.1 Past

  • CYAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.28%, which is quite impressive.
  • The Revenue has grown by 158.33% in the past year. This is a very strong growth!
  • Measured over the past years, CYAD shows a very strong growth in Revenue. The Revenue has been growing by 98.73% on average per year.
EPS 1Y (TTM)33.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.68%
Revenue 1Y (TTM)158.33%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%0%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYAD.BR Yearly Revenue VS EstimatesCYAD.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2023 2024 2M 4M 6M 8M
CYAD.BR Yearly EPS VS EstimatesCYAD.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. CYAD.BR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CYAD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYAD.BR Price Earnings VS Forward Price EarningsCYAD.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYAD.BR Per share dataCYAD.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYAD.BR Dividend Analysis

5.1 Amount

  • CYAD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYAD.BR Fundamentals: All Metrics, Ratios and Statistics

CELYAD ONCOLOGY

EBR:CYAD (3/5/2026, 9:00:59 AM)

0.379

+0.02 (+5.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-25
Earnings (Next)N/A
Inst Owners58.59%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap8.56M
Revenue(TTM)186.00K
Net Income(TTM)-6.46M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.04
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.01
BVpS-0.14
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -113.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.09%
FCFM N/A
ROA(3y)-106.06%
ROA(5y)-75.47%
ROE(3y)-740.65%
ROE(5y)-467.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.66
Quick Ratio 0.59
Altman-Z -6.19
F-Score3
WACC7.54%
ROIC/WACCN/A
Cap/Depr(3y)50.8%
Cap/Depr(5y)39.13%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.68%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)158.33%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%0%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.43%
OCF growth 3YN/A
OCF growth 5YN/A

CELYAD ONCOLOGY / CYAD.BR FAQ

What is the ChartMill fundamental rating of CELYAD ONCOLOGY (CYAD.BR) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CYAD.BR.


What is the valuation status for CYAD stock?

ChartMill assigns a valuation rating of 0 / 10 to CELYAD ONCOLOGY (CYAD.BR). This can be considered as Overvalued.


What is the profitability of CYAD stock?

CELYAD ONCOLOGY (CYAD.BR) has a profitability rating of 1 / 10.